Sutro Biopharma ' s Lead Ovarian Cancer Candidate Is A Game Changer, Analyst Sees Huge Upside

Oppenheimer initiated coverage on Sutro Biopharma Inc STRO, representing around 200% potential upside. The analysts Jay Olson and Matthew Hershenhorn view Sutro as a unique clinical-stage company pioneering the development of next-generation antibody-drug conjugates (ADCs), a growing area of…#oppenheimer #sutrobiopharmainc #jayolson #matthewhershenhorn #sutro #folrα #immunogeninc #imgnelahere #luvelta #imgn
Source: Reuters: Health - Category: Consumer Health News Source Type: news